High-affinity immunoglobulin epsilon receptor I-bound immunoglobulin E complex (IgE-FcεRI complex) (IgE-FcεRI complex)

The High-affinity immunoglobulin epsilon receptor I-bound immunoglobulin E (IgE-FcεRI) complex is the central molecular assembly responsible for triggering allergic inflammatory responses in mast cells and basophils (Kinet, J. P., 1999, Annual Review of Immunology) [1]. This complex is formed when monomeric IgE binds to the alpha subunit of the FcεRI receptor with exceptionally high affinity, sensitizing the cell to specific allergens (Garman, S. C., et al., 2000, Nature) [2]. Upon subsequent exposure, multivalent allergens cross-link these pre-formed complexes, initiating an intracellular signaling cascade involving tyrosine kinases like Lyn and Syk, which ultimately leads to the rapid release of pre-formed mediators such as histamine and the synthesis of leukotrienes and cytokines (Siraganian, R. P., 2003, FEBS Letters) [3]. In clinical pathology, the density of these complexes on the cell surface is directly correlated with serum IgE levels, as IgE binding stabilizes the receptor and prevents its internalization, thereby amplifying allergic sensitivity (Kawakami, T., & Galli, S. J., 2002, Nature Reviews Immunology) [4]. Therapeutic intervention typically involves the use of monoclonal antibodies like Omalizumab, which bind to the Cε3 domain of free IgE to prevent its association with FcεRI, effectively reducing the number of active complexes over time (Schulman, E. S., 2001, American Journal of Respiratory and Critical Care Medicine) [5]. Emerging therapies also target downstream signaling components of the complex, such as Bruton's tyrosine kinase (BTK), to mitigate the effector functions of mast cells and basophils in diseases like chronic spontaneous urticaria and asthma (Maurer, M., et al., 2019, Journal of Allergy and Clinical Immunology) [6].

Other names

FcεRI-IgE complexHigh-affinity IgE receptor-IgE complexMast cell IgE receptor complexFcεRI-bound IgE

Therapeutic agents primarily act by sequestering free IgE to prevent the formation of new IgE-FcεRI complexes and induce receptor downregulation, or by inhibiting downstream signaling molecules like Bruton's tyrosine kinase (BTK) to block mediator release from existing complexes.